文献速递肝病

肌因子与酒精相关性肝病的进展、病程及死亡率相关

Myokines are associated with progression, course and mortality in alcohol-associated liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-08-12

研究纳入2021至2023年301例酒精相关性肝病患者,涵盖脂肪肝、代偿期肝硬化、非急性失代偿、急性失代偿和慢加急性肝衰竭。结果显示肌生成抑制素随肝病进展升高、核心蛋白聚糖降低,两者与营养不良、炎症、器官衰竭、病程及30天死亡率相关;核心蛋白聚糖可增强MELD对急性失代偿和慢加急性肝衰竭死亡风险的评估。

要点

  • 肌生成抑制素随肝病进展升高,核心蛋白聚糖降低,与器官衰竭分级相关。
  • 基线核心蛋白聚糖可预测急性失代偿和慢加急性肝衰竭的病情缓解。
  • 核心蛋白聚糖是死亡的独立预测因子,并与MELD联合增强风险估计。

核心结论

  • 肌因子与酒精相关性肝病的营养不良、纤维化、全身炎症、器官衰竭、病程及死亡率相关。
  • 核心蛋白聚糖可增强MELD对急性失代偿和慢加急性肝衰竭患者死亡风险的评估。
  • 肌因子的治疗性调节是酒精相关性肝病潜在的疾病修饰靶点。

研究设计与样本

  • 研究纳入2021至2023年301例酒精相关性肝病患者,包括脂肪肝13例、代偿期肝硬化17例、非急性失代偿95例、急性失代偿51例和慢加急性肝衰竭125例。
  • 记录血浆肌生成抑制素、核心蛋白聚糖水平、营养状态、握力、全身炎症、感染、血氨、病程及30天死亡率。

主要发现

  • 患者年龄48岁(IQR:38-52),男性占97.7%。
  • 肝硬化患者较无肝硬化者肌生成抑制素升高、核心蛋白聚糖降低,失代偿期肝硬化较代偿期肝硬化进一步变化(p < 0.001)。
  • 从非急性失代偿到急性失代偿再到慢加急性肝衰竭,肌生成抑制素逐步升高、核心蛋白聚糖逐步降低(p < 0.001)。
  • 在急性失代偿和慢加急性肝衰竭中,肌生成抑制素随分级和器官衰竭进一步升高,核心蛋白聚糖进一步降低(p < 0.001)。
  • 基线核心蛋白聚糖预测急性失代偿和慢加急性肝衰竭病情缓解的AUC为0.797,与MELD联合的AUC为0.814。

关键数值与推荐

  • 肌生成抑制素预测死亡的校正OR为18.96,核心蛋白聚糖的校正OR为0.02。
  • 核心蛋白聚糖是死亡的独立预测因子(校正OR:0.04),并与MELD联合增强风险估计(MELD+logDecorin+logTLC+HE-grade的AUC为0.815;p < 0.05)。
  • 在急性失代偿和慢加急性肝衰竭中,肌生成抑制素升高和核心蛋白聚糖降低与炎症、高氨血症、营养不良和握力相关(p < 0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Myokines are the muscle-derived hormones orchestrating muscle and systemic health. Their role in the progression of alcohol-associated liver disease (ALD) remains elusive. METHODS: Three-hundred-one patients across the spectrum of ALD including fatty liver (FL, N = 13), compensated cirrhosis (CC, N = 17), non-acute decompensation (NAD, N = 95), acute decompensation (AD, N = 51) and acute-on-chronic liver failure (ACLF, N = 125) were recruited between 2021 and 2023. Plasma myostatin, decorin levels, nutritional status, handgrip strength (HGS), systemic inflammation, infection, ammonia, disease course and 30-day mortality were recorded. RESULTS: Patients aged 48 years (IQR: 38-52) and 97.7% of males were enrolled. Myostatin was elevated while decorin was reduced in cirrhosis compared to without cirrhosis, and further in DC compared to CC (p < 0.001). A step-wise increase in myostatin and reduction in decorin was observed transitioning from NAD to AD to ACLF (p < 0.001). Myostatin was further increased and decorin was reduced along with the grades and organ failures in AD and ACLF (p < 0.001, each). Baseline decorin (AUC: 0.797) and its combination with MELD (AUC: 0.814) predicted disease resolution in AD and ACLF. Although, both myostatin (aOR: 18.96) and decorin (aOR: 0.02) could predict mortality, decorin was independent (aOR: 0.04) and additive to MELD (AUC of MELD+logDecorin + logTLC + HE-grade:0.815); p < 0.05 each. Myostatin increased and decorin reduced with inflammation, hyperammonaemia, malnutrition and HGS in AD and ACLF (p < 0.05, each). CONCLUSION: Myokines are linked with malnutrition, fibrosis, systemic inflammation, organ failures, disease course and mortality in ALD. Decorin enhances the risk estimation of mortality of MELD in AD and ACLF. Therapeutic modulation of myokines is a potentially disease-modifying target in ALD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kaur P, Verma N, Garg P, et al. Myokines are associated with progression, course and mortality in alcohol-associated liver disease. Aliment Pharmacol Ther. 2024. PMID: 39135311. doi:10.1111/apt.18202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。